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SUMMARY
Screening blood donations for anti-HCV antibodies and alanine aminotransferase (ALT) serum levels generally prevents the
transmission of hepatitis C virus (HCV) by transfusion. The aim of the present study was to evaluate the efficiency of the enzyme
immunoassay (EIA) screening policy in identifying potentially infectious blood donors capable to transmit hepatitis C through blood
transfusion. We have used a reverse transcriptase (RT)-nested polymerase chain reaction (PCR) to investigate the presence of HCV-
RNA in blood donors. The prevalence of HCV-RNA positive individuals was compared with the recombinant immunoblot assay
(RIBA-2) results in order to assess the usefulness of both tests as confirmatory assays. Both tests results were also compared with the
EIA-2 OD/C ratio (optical densities of the samples divided by the cut off value). ALT results were expressed as the ALT quotient
(qALT), calculated dividing the ALT value of the samples by the maximum normal value (53UI/l) for the method. Donors (n=178)
were divided into five groups according to their EIA anti-HCV status and qALT: group A (EIA3, ALT<1), group B (EIA3, ALT>1),
group C (1EIA<3, ALT<1), group D (1EIA<3, ALT>1) and group E (EIA0.7). HCV sequences were detected by RT-nested PCR,
using primers for the most conserved region of viral genome. RIBA-2 was applied to the same samples. In group A (n=6), all samples
were positive by RT-nested PCR and RIBA-2. Among 124 samples in group B, 120 (96.8%) were RIBA-2 positive and 4 (3.2%) were
RIBA-2 indeterminate but were seropositive for antigen c22.3. In group B, 109 (87.9%) of the RIBA-2 positive samples were also RT-
nested PCR positive, as well as were all RIBA-2 indeterminate samples. In group C, all samples (n=9) were RT-nested PCR negative:
4 (44.4%) were also RIBA-2 negative, 4 (44.4%) were RIBA-2 positive and 1 (11.1%) was RIBA-2 indeterminate. HCV-RNA was
detected by RT-nested PCR in 3 (37.5%) out of 8 samples in group D. Only one of them was also RIBA-2 positive, all the others were
RIBA-2 indeterminate. All of the group E samples (controls) were RT- nested PCR and RIBA-2 negative. Our study suggests a strong
relation between anti-HCV EIA-2 ratio  3 and detectable HCV-RNA by RT-nested PCR. We have also noted that blood donors with
RIBA-2 indeterminate presented a high degree of detectable HCV-RNA using RT-nested PCR (75%), especially when the c22.3 band
was detected.
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INTRODUCTION
Since the cloning and characterization of hepatitis C virus (HCV)3
as the major cause of post-transfusion non-A, non-B hepatitis around
the world5,12,20, a number of serological tests using recombinant and/or
synthetic polypeptides derived from the HCV genome have been
developed to detect circulating antibodies. The first-generation anti-HCV
enzyme immunoassay (EIA-1) detected only antibodies to the
recombinant HCV antigen c100-312. The use of this test to low risk
populations such as blood donors resulted in a high number of false-
positive and false-negative results4,9,16. The second generation HCV EIA
(EIA-2) assay relies on the detection of antibodies against two additional
antigens: c33c (in the NS3 region, that codes the putative protease/
helicase) and c22-3 (in the core region)29. In the third-generation EIA
(EIA-3) peptides from the NS5 region and some recombinant antigens
from other regions have been replaced by synthetic peptides25. The
improvement in sensitivity and specificity from EIA-2 to EIA-3 was not
so important as the improvement observed from EIA-1 to EIA-2. The
average period for HCV seroconversion after blood transfusion has been
shortened with each new generation: 7 to 8 weeks for EIA-3 compared
with 10 weeks for EIA-2 and 16 weeks for EIA-18. Incorporating these
new antigens improved the sensitivity of the assay but the question of
specificity remains open6,8,15. Thus, in EIA-positive cases, it is important
to confirm these tests results using other assays.
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A possible supplementary test is the recombinant protein immunoblot
assay, also available as a second-generation test (RIBA-2)26. In addition to
the three recombinant antigens mentioned above, this test also utilizes the
recombinant protein 5-1-1 and superoxide dismutase (SOD)27. Recently,
a more sensitive third-generation of RIBA (RIBA-3) has been introduced
and uses the same antigens as the EIA-3. Another approach relies on the
detection of HCV-RNA by the RT polymerase chain reaction (PCR)28.
Using PCR, the presence of HCV-RNA can be confirmed in samples with
positive or indeterminate EIA results. Hepatitis C viremia is known to be
present in most patients with chronic hepatitis C, including those with a
long-standing infection or advanced liver disease such as cirrhosis or
hepatocellular carcinoma10. Most (80%-90%) EIA-2-positive patients with
chronic hepatitis C are RIBA-2 and HCV-RNA positive while
approximately 10% are RIBA indeterminate and 60%-70% of whom will
be HCV-RNA positive2,14. Contrary to patients with chronic liver disease,
only 36% to 65%, anti-HCV (EIA-2) positive blood donors are RIBA
positive and 20% to 30% are RIBA indeterminate. The percentage of EIA-
2-positive blood donors who have detectable HCV-RNA in serum when
tested by RT-PCR varies from 70% to 90% for those who are RIBA positive
to 2% to 40% for those who are RIBA indeterminate18,23,24.
The aim of the present study was to evaluate the efficiency of the
EIA screening policy in identifying potentially infectious blood donors
capable to transmit hepatitis C through blood transfusion at an University
Hospital Blood Bank at Campinas, São Paulo, Brazil. We have used a
reverse transcriptase (RT)-nested PCR to investigate the presence of HCV-
RNA in blood donors. The prevalence of HCV-RNA positive individuals
was compared with the RIBA-2 results in order to assess the usefulness
of both tests as confirmatory assays and EIA-2 ratio.
MATERIALS AND METHODS
Blood donors: Hepatitis C-infected blood donors in this study were
identified during routine screening for HCV antibodies after blood
donation. In our blood bank, annually around 30,000 units of blood are
collected and we have 1.9 - 2.1% of positivity for anti-HCV by EIA-2
test. The 178 blood donors selected were classified according to their
anti-HCV status and alanine-aminotransferase (ALT) level. One hundred
and forty-seven (82.6%) were anti-HCV reactive and 31 (17.4%) were
anti-HCV negative. All selected blood samples tested were negative for
anti-HIV 1/2, anti-HTLV I/II, HBsAg and anti-HBc, as well as for markers
for Chagas’ disease and syphilis (see Table 1).
Anti-HCV screening: Serum samples were screened using a second-
generation HCV enzyme immunoassay (HCV EIA, Abbott Laboratories,
Diagnostic Division, North Chicago, IL, USA). The tests were performed
according to the manufacturer’s instructions. The results of anti-HCV
EIA-2 test were expressed as the optical densities (OD) of the samples
divided by the cut off value (C). The mean of three results obtained
when it was retested was used to calculate the EIA ratio OD/C of each
reagent or indeterminate samples. So, the ratio OD/C  0.7 was
considered non-reagent and was weakly reagent when the ratio OD/C
was  1 and < 3. Samples with ratio OD/C 3 were considered highly
reagent. Samples with ratio OD/C between 0.7-0.99 were not studied.
Alanine-aminotransferase (ALT) determinations: ALT levels were
determined using a commercial kit (SGPT ALT, Abbott) and the normal
reference interval were 0-53 UI/l. The results were expressed as the ALT
quotient (qALT), calculated dividing the ALT value of the samples by
the maximum normal value for the method. When the ALT level was
elevated qALT was always >1.
Recombinant protein immunoblot assay: All samples were tested
using a second-generation immunoblot assay, RIBA-2 (Ortho Diagnostic
Systems, Raritan, NJ, USA). The tests were performed and evaluated as
described by the manufacturer. For the RIBA-2, samples reacting with
at least two bands were considered positive, whereas samples reacting
with only one band were considered indeterminate. Samples with no
seroreactivity to any HCV recombinant antigen were considered RIBA-
2-negative.
cDNA synthesis: Sera from blood donors were stored at –20 °C.
For the reverse transcription (RT)-PCR amplification of HCV from human
serum, we used a simple rapid method that does not require the RNA
extraction step21. After denaturation (30 s at 92 °C), 3 l of serum were
added to the RT mixture (50 mM Tris-HCl, pH 8.2, 70 mM KCl, 10 mM
MgCl2, 4 mM DTT, 12 units of human placental ribonuclease inhibitor
(RNAguard, Pharmacia, Uppsala, Sweden), 0.4% Nonidet P-40, 50
pmoles of a specific antisense primer (R1), 250 mM dNTPs and 6 units
of avian myeloblastosis virus reverse transcriptase (AMV-RT, United
State Biochemical Corp, Cleveland, OH), in a final volume of 25 l).
RT was carried out at 42 °C for 60 min and the resulting cDNA was
immediately denatured by heating for 5 min at 100 °C.
Nested PCR assay: Two primer sets were used to amplify the HCV
sequences. Each set consisted of two “outer” primers F1 (5’ -
GGCGACACTCCACCATAGATC - 3’) and R1 (5’-
GGTGCACGGTCTACGAGACCT - 3’), which generated a PCR product
of 324 bp and two “inner” primers F3 (5’-
CTGTGAGGAACTACTGTCTTC - 3’) and R3 (5’-
CCCTATCAGGCAGTACCACAA - 3’) which generated a PCR product
of 256 bp (nested PCR)7. Both primer sets correspond to sequences in
the 5’-non-coding region (NCR) of the HCV genome.
Five microliters of cDNA were denatured for 5 min at 94 °C in 45 l
of PCR buffer (20 mM of Tris-HCl, pH 8.4, containing 50 mM KCl and
Table 1
Classification of 178 blood donors according to their EIA-2 results and qALT
levels
qALT*
ALT <1  ALT> 1 TOTAL
EIA* N° % N° % N° %
EIA 3 6[A] (4.6) 124[B] (95.4) 130 (100)
1 EIA <3 9[C] (52.9) 8[D] (47.1) 17 (100)
EIA < 0.7 31[E] -(0) -(0) -(0) 31 (100)
TOTAL 46 (25.8) 132 (74.2) 178 (100)
EIA* = Enzyme immunoassay optical density value/cut off
qALT* = alanine-aminotransferase values expressed as a ratio of the samples
value/upper normal value
[A], [B], [C], [D], [E] =  resulting groups of patients.
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2 mM MgCl2) together with 100 pmol of both “outer” primers and 200
mM of each dNTP. This reaction mixture was covered with 100 l of
mineral oil. Following the denaturation step, 2.5 units Thermus aquaticus
DNA polymerase (Bethesda Research Laboratories, Life Technologies
Inc., Gaithersburg, Maryland) were added, and the samples were
submitted to 35 cycles of amplification as follows: 1 min at 94 °C, 1 min
at 55 °C and 1 min at 72 °C in a DNA Thermal Cycler (Perkin Elmer
Cetus, Foster City, CA, USA). Five microliters of the newly amplified
material were then submitted to a second round of amplification using
the “inner” primers. Following denaturation, 30 cycles of amplification
were performed with each cycle consisting of 1 min at 94 °C, 1 min at
55 °C and 1 min at 72 °C. A final step (7 min at 72 °C) was included
after the last cycle of both the first and second rounds of amplification.
For each PCR assay, water was used as a negative control and serum
from one individual HCV positive by EIA and confirmed by RT-PCR
and liver biopsy was used as a positive control. Carryover contamination
was prevented as described by KWOK & HIGUCHI13. The final
amplification product was mixed with bromphenol blue, electrophoresed
in a 2% agarose gel, stained with ethidium bromide, visualized and
photographed as previously described28. Samples were considered
positive if they yielded at least two positive results from three
amplifications. Negative samples showed two negative results from two
different reactions.
Statistical analysis: The 2 test and Fisher exact test correction were
used to analyze the data.
RESULTS
The samples were classified according to their EIA ratio and qALT
(Table1). The RT-nested PCR and RIBA-2  results for these samples
were described below (see Table 2).
Group A (n=6): All 6 cases with EIA ratio  3 and qALT<1 were
RT-nested PCR and RIBA-2 positive.
Group B (n=124): In this group with EIA ratio  3 and qALT>1,
120 (96.8%) were RIBA-2 positive and 4 (3.2%) were RIBA-2
indeterminate with seropositivity only to antigen c22.3. One hundred
and nine (87.9%) samples were both RT-nested PCR and RIBA-2 positive
and all RIBA-2 indeterminate samples were RT-nested PCR positive.
Group C (n=9): All the samples with EIA ratio  1 and < 3 and
qALT<1 were RT-nested PCR negative. Concerning RIBA-2 results, 4
(44.4%) samples were negative, 4 (44.4%) were positive and one was
indeterminate.
Group D (n=8): In this group, with EIA ratio  1 and < 3 and qALT>1,
the RT-nested PCR detected three positive samples (37.5%), only one of
them was also RIBA-2 positive.
Group E (n=31): In this group (controls), with EIA ratio  0.7 and
qALT <1, all of the samples were RT-nested PCR and RIBA-2 negative.
Relationship between RIBA-2 indeterminate and RT- nested PCR
results: Eight out of 178 sera (4.5%) were indeterminate by the RIBA-
2. Among these samples, 6 (75%) were positive by RT-nested PCR. Seven
out of 8 RIBA-2 indeterminate cases were due to seropositivity to c22.3
and one case to seropositivity to c33c. The six RT-nested PCR positive
cases were also positive for c22.3 antigen.
Assessment of divergent results in RT-nested PCR and RIBA-2:
Divergent results were considered when a negative result was obtained
with one assay, while a positive or indeterminate result was obtained
with the other. Twenty-one (11.8%) divergent results were obtained using
RT-nested PCR and RIBA-2. In two of these, the RIBA-2 result was
indeterminate, while this result was positive, in the other 19 cases, in
spite of the a negative RT-nested PCR result.
DISCUSSION
The current strategy in Brazil for the prevention of transfusion-
associated hepatitis C relies on the screening of blood donations for
anti-HCV and determination of ALT levels. To prevent HCV
transmission, all blood donations positive for HCV antibody and/or
elevated (>53U/l) ALT levels are discarded. Second generation EIA test
for HCV antibody yields greater specificity and sensitivity. However,
McHUTCHISON et al.15 found little improvement in specificity when
testing a low-risk population, although a correlation between optical
density values and the presence of HCV RNA was observed.
Supplementary tests such as the recombinant protein immunoblot
assay (RIBA-2) or RT-nested PCR can be applied to EIA-2 reactive
Table 2
Results of the RT-nested PCR and RIBA-2 assays in the five groups of donors
 Group RT-nested PCR a         RIBA-2 RIBA+/PCR+
    (+) (-) (+) (-) Indb
A (n=6) % 6 (100) -(0) 6 (100) -(0) -(0) 6 (100)
B (n=124) % 113 (91.1) 11 (8.9) 120 (96.8) -(0) 4c(3.2) 109 (87.9)
C (n=9) % -(0) 9 (100) 4 (44.4) 4 (44.4) 1 (11.2) -(0)
D (n=8) % 3 (37.5) 5 (62.5) 5 (62.5) -(0) 3d (37.5) 1 (12.5)
E (n=31) % -(0) 31 (100) -(0) 31 (100) -(0) -(0)
Total 122 56 135 35 8 116
a= includes samples with at least one positive result in the RT-nested PCR assay (HCV-RNA positive)
b= RIBA-2 indeterminate
c = RIBA –2 indeterminate were positive by RT-nested PCR
d = two of these RIBA-2 were positive by RT-nested PCR
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samples, thereby improving the reliability of the HCV diagnosis1. We
applied both of these tests to 178 sera, classified according to their EIA-
2 ratio and qALT level. The detection of HCV-RNA by PCR was
considered the standard marker for infectivity.
To limit the occurrence of false-negatives in the RT-nested PCR assay,
we used primers in the 5’-noncoding region of the HCV genome, which
is over 98% conserved among different isolates17.
In our study, we observed a very good relation between the RT-
nested PCR and RIBA-2 results in group B (Table 2), with no significant
difference between the two tests (p>0.05). In 87.9% of  HCV-RNA-
positive donations, the presence of anti-HCV was also confirmed by
RIBA-2. This proportion is greater than the 36% of RIBA-2 positive
cases reported in similar individuals in studies conducted in Italy18,22 and
France24 and 39% observed in USA11. In Spain, 33-63% of anti-HCV
positive was also RIBA-2 positive19,23. The discrepancy between our
results and these cited above may be related to the type of donor included
in our evaluation (EIA>3 and qALT>1). In 11 (8.9%) samples, the
reactivity in RIBA contrasted with no reactivity by RT-nested PCR. The
question of whether RIBA-2-positive/HCV-RNA-negative results reflect
low levels of viremia, loss of infectivity, or failure of the RT-nested PCR
assay can be answered only after those donors have been followed and
other samples from them could be tested.
The RIBA-2 indeterminate results were generally associated with
the presence of HCV-RNA in peripheral blood. The high rate of RIBA-
2 indeterminate with positive RT-nested PCR results was correlated with
the presence of antigen c22.3 in all cases. For this reason, we considered
as obligatory to screen RIBA indeterminate donors for HCV-RNA.
ALT screening in conjunction with anti-HCV EIA ratio proved to
be valuable in identifying potentially infectious donors capable of
transmitting hepatitis C mainly in donors with EIA-2 ratio  3. We
observed that donors with anti-HCV ratio  3 and qALT <1 (group A)
were HCV-RNA positive. The high anti-HCV EIA-2 ratio ( 3), was
also associated with a positive RT-nested PCR result among donors in
group B (113/124-91%). RT-nested PCR was positive in 119/130 (91.5%)
donors with EIA-2 ratio  3 (groups A and B), while only 3/17 (17.6%)
were HCV-RNA positive among donors with EIA-2 ratio  1 and < 3
(groups C and D). These data show that elevated EIA-2 ratio  3 is
associated to RT-nested PCR positivity in anti-HCV positive patients.
A substantially higher rate of viremia as well as anti-HCV positivity
confirmed by RIBA-2 was observed for donors in group B compared to
group D (87.9% vs 12.5%- p<0.05). The RIBA-2 can exclude false EIA-
2 reactivities and identify positives fairly well, as judged from the PCR
analysis of group D. For the moment, the RIBA-2 should be regarded as
confirmatory for anti-HCV EIA-2 reactivity. Although there was a rather
strong association between RIBA-2 and RT-nested PCR, some infectious
donors will not be detected by the RIBA-2 assay. On the other hand, the
RT-nested PCR is very sensitive and specific in detecting viremia and,
hence, potentially infectious donors.
Our study suggested a strong correlation between anti-HCV EIA-2
ratio  3 and HCV-RNA positivity by PCR. We have also noted that blood
donors with RIBA-2 indeterminate presented high degree of positivity in
PCR (75%) mainly when they had positivity in the c22.3 band.
RESUMO
Diagnóstico da hepatite por vírus C em doadores de sangue
brasileiros, usando a reação de transcrição reversa e a reação em
cadeia da polimerase “nested”: comparação com os ensaios
imunoenzimáticos e imunoblot recombinante
Na prevenção da transmissão de Hepatite por Vírus C (HCV) em
transfusões de hemocomponentes, utiliza-se rotineiramente, como testes
de triagem de doadores de sangue, ensaios que detectam anticorpos anti-
HCV e dosagens da enzima alanina-aminotransferase (ALT). O presente
estudo tem como objetivo principal avaliar a eficiência do ensaio
imunoenzimático de segunda geração (EIA-2) como teste de triagem,
na identificação de doadores de sangue potencialmente infectados, e
portanto, capazes de transmitir hepatite C pelos hemocomponentes. Nós
utilizamos o ensaio de transcrição reversa (RT) e a reação em cadeia da
polimerase “nested” («nested PCR») para investigar a presença do RNA
do vírus da hepatite C (HCV) em doadores de sangue. A prevalência do
RNA-HCV em indivíduos positivos foi comparada com os resultados
do ensaio complementar  imunoblot recombinante de segunda geração
(RIBA-2) com o intuito de avaliar a utilidade de ambos como testes
confirmatórios. Estes  dois testes também foram comparados com a razão
DO/C (valores de densidade óptica das amostras dividida pelo valor de
corte da reação) no EIA-2. Os resultados das dosagens da ALT foram
expressos como uma razão unitária denominada qALT, que representa o
cálculo do valor do ALT da amostra dividido pelo valor máximo
considerado normal para o teste (53UI/L). Os doadores de sangue foram
divididos em cinco grupos de acordo com os resultados do EIA-2 e o
qALT: grupo A (EIA3, ALT<1), grupo B (EIA3, ALT>1), grupo C
(1EIA<3, ALT<1), grupo D (1EIA<3, ALT>1) e grupo E (EIA0,7).
As seqüências do HCV foram detectadas por RT-nested PCR, utilizando-
se os “primers” da região mais conservada do genoma viral. O teste
RIBA-2 foi aplicado nas mesmas amostras. No grupo A (n=6) todas as
amostras foram positivas para o RT-nested PCR e RIBA-2. Entre as 124
amostras do grupo B, 120 (96,8%) eram RIBA-2 positivas e 4 (3,2%)
eram RIBA-2 indeterminadas mas positivas para o antígeno c22.3. No
grupo B, as 109 amostras (87,9%) RIBA-2 positivas também
apresentaram RT-nested PCR positivas, bem como todas as amostras
com RIBA-2 indeterminadas. No grupo C, todas as amostras (n=9) foram
RT-nested PCR negativas: 4 (44,4%) apresentaram também RIBA-2
negativa enquanto que 4 (44,4%) foram RIBA-2 positivas e 1(11,1%)
foi RIBA-2 indeterminada. O RNA-VHC foi detectado por RT-nested
PCR em 3 (37,5%) das 8 amostras do grupo D. Todas as amostras do
grupo E (controle) foram RT-nested PCR e RIBA-2 negativas. Nosso
estudo sugere uma forte relação entre a razão anti-HCV EIA-2 3 e a
positividade do RNA-HCV por RT-nested PCR. Nós também pudemos
observar que os doadores de sangue com RIBA-2 indeterminados
apresentaram um alto grau de positividade no RT-nested PCR (75%),
especialmente quando está presente a banda correspondente ao antígeno
c22.3.
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